Fig. 4From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisA A comparison of infliximab versus vedolizumab for key safety outcomes in patients with Crohn’s disease (≤ 1 year) Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumab. B. A comparison of infliximab versus vedolizumab for key safety outcomes in patients with ulcerative colitis (≤ 1 year). Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumabBack to article page